MURANO trial

The MURANO trial was a clinical study that tested a targeted cancer treatment called ibrutinib combined with venetoclax for patients with chronic lymphocytic leukemia (CLL). It aimed to see if this combo could better control the disease compared to traditional therapies. The results showed that patients receiving the combination had higher remission rates, longer periods without disease progression, and fewer side effects. This study demonstrated that this targeted, time-limited therapy could be a highly effective and potentially more convenient option for treating CLL.